Starling Oncology (STLNW) Change in Account Payables (2020 - 2026)

Starling Oncology (STLNW) has reported Change in Account Payables for 7 consecutive years, with $12.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Change in Account Payables rose 94.33% year-over-year to $12.5 million; the trailing twelve-month figure through Jun 2026 stood at $25.3 million (up 27.53% YoY), and the FY2025 full-year result was $19.6 million, up 113.11% from the prior year.
• Change in Account Payables climbed to $12.5 million in Q2 2026 per STLNW's latest filing, from $4.6 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $12.5 million in Q2 2026 and bottomed at -$5.5 million in Q2 2024.
• Historically, Change in Account Payables has averaged $2.5 million across 5 years, with a median of $1.2 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Change in Account Payables tumbled 725.11% in 2022, then soared 3508.57% in 2024.
• Over 5 years, Change in Account Payables stood at -$1.8 million in 2022, then soared by 161.47% to $1.1 million in 2023, then slumped by 32.57% to $739000.0 in 2024, then surged by 943.17% to $7.7 million in 2025, then soared by 62.16% to $12.5 million in 2026.
• According to Business Quant data, Change in Account Payables over the past three periods registered $12.5 million, $4.6 million, and $7.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.